Under a tenth of people who could benefit from obesity jabs such as Wegovy have access to them, states the World Health Organization as it publishes its first guidance on the drugs.
With more than one billion individuals worldwide currently living with obesity, it is urging increased and just availability to this class of drugs.
Based on forecasts, over two billion could be obese by 2030 unless action is taken.
"Our latest guidance acknowledges that excess weight is a long-term condition that can be addressed with holistic and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are key obstacles to widespread availability to the jabs that can help people shift substantial body mass, notes the organization.
Despite the present best projected case, the supply of such drugs could only cover around 100 million people – under 10% of those who need them, as stated by the health organization.
The advice encourages governments and firms to increase availability, via strategies like licensing agreements.
Exclusive production rights on the active ingredient – the primary ingredient of the drug Wegovy – is set to lapse in multiple countries in 2026.
The injections imitate a body's own hormone to delay gastric emptying, curb appetite and increase the sense of being full so people reduce food intake.
People typically begin shedding pounds within a few weeks of commencing the regular doses.
Evidence indicates patients may put most of the weight back on within a year of halting the treatment, because their typical hunger return.
To be carrying excess weight increases your risk for developing diseases, including diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity concerns individuals in countries worldwide and was responsible for millions of deaths worldwide in 2024, according to the health agency.
A tech journalist and digital strategist with over a decade of experience covering emerging technologies and startup ecosystems.